We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Cepheid Unveils Third-Generation GeneXpert System at ADLM 2026

By LabMedica International staff writers
Posted on 27 Jul 2026

Cepheid  is unveiling the third generation of its GeneXpert molecular diagnostic system at the Association for Diagnostics & Laboratory Medicine (ADLM) 2026 Annual Scientific Meeting. More...

The company is presenting the new platform during a special event on Tuesday, July 28, highlighting its expanded capabilities for PCR-based testing.

The third-generation GeneXpert system is designed to broaden the range of molecular testing available on a single platform while retaining the simplicity, flexibility, and reliability of existing GeneXpert workflows. According to the company, the system supports laboratories seeking to consolidate different types of molecular testing that may otherwise require multiple instruments and processes.

At launch, the platform is designed to support Cepheid’s comprehensive menu of U.S. Food and Drug Administration-cleared Xpert tests. It introduces a fully integrated touchscreen interface, redesigned software, and a more intuitive user experience while maintaining the workflows currently used by GeneXpert customers.

The system is also being developed to support a new generation of Xpert tests and applications. Planned capabilities include high-plex panel testing, faster time to results, and additional sample-to-answer solutions that could extend to next-generation sequencing workflows.

Like the company’s existing GeneXpert systems, the new platform provides random-access testing, allowing laboratories to process samples as they arrive rather than waiting to assemble batches. This approach enables urgent samples to be prioritized while supporting rapid access to actionable results across different healthcare environments.

The first configuration scheduled for release is a compact four-module system, with shipments to U.S. customers expected to begin in the coming months. Cepheid is also developing higher-capacity GeneXpert configurations and new GeneXpert Infinity systems for laboratories with larger testing volumes. The systems remain in development and have not been reviewed by a regulatory authority for diagnostic use.

Cepheid’s unveiling forms part of Danaher’s broader presence at ADLM 2026. At booth 3237, visitors can explore technologies from Danaher operating companies including Beckman Coulter Diagnostics, Beckman Coulter Life Sciences, Cytiva, HemoCue, Leica Biosystems, Radiometer, and SCIEX, covering diagnostic and life sciences workflows from discovery through clinical delivery.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.